Despite assurances from Merck & Co. Inc. that their recent decision to withhold their version of Sanofi’s Lantus (insulin glargine) from the US market does not signify a waning commitment to producing biosimilars, it could signify a softening of interest in the market in the US.
On the heels of some lackluster launches of biosimilars stateside, Merk’s decision to refrain from commercializing their tentatively FDA approved Lusduna could signify trouble for the near-term commercial potential for biosimilars, a sentiment echoed by FDA Commissioner Scott Gottlieb, himself. Find out more in this illuminating article from Scrip.
On the heels of some lackluster launches of biosimilars stateside, Merk’s decision to refrain from commercializing their tentatively FDA approved Lusduna could signify trouble for the near-term commercial potential for biosimilars, a sentiment echoed by FDA Commissioner Scott Gottlieb, himself. Find out more in this illuminating article from Scrip.
